Sign Up to like & get
recommendations!
1
Published in 2021 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-002680
Abstract: Introduction Several studies have shown clinical outcomes data that support the use of CD274 (PD-L1) copy-number (CN) gains and/or losses as a biomarker for immune checkpoint inhibitor (ICPI). Here, we present the landscape of CD274…
read more here.
Keywords:
tumor types;
cd274 changes;
244 584;
cd274 ... See more keywords